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ABSTRACT 
Lymphomas are generally not considered as endocrine-associated cancers. Nevertheless, most 
lymphoid malignancies show a gender difference in incidence and prognosis, with males 
being more affected. The molecular mechanism for this gender difference is unknown. Some 
epidemiological data show a protective function of estrogens against Non-Hodgkin 
lymphomas (NHL). Recent  studies  have demonstrated estrogen receptor β (ERβ) to be the 
major ER expressed in normal and malignant cells of lymphoid lineage. 
In Paper I, we demonstrated a gender differences in tumor growth by grafting mice with 
murine T lymphoma cells. We found that  male mice developed larger tumors compared to 
female mice, a difference that was abolished following ovariectomy, suggesting estrogen 
regulated growth in vivo. In addition, we looked into the effects of 17β-estradiol, selective 
ERα and selective ERβ agonists on lymphoma growth in culture and in vivo. Treatment 
with 17β-estradiol had minor effects on lymphoma growth, whereas the selective ERβ 
agonists diarylpropionitrile (DPN) and KB9520 showed potent antiproliferative and 
proapoptic effect. This study for the first time showed in vivo that ERβ agonists may be 
useful in the treatment of lymphomas. 
In Paper II, we studied ligand-activated ERβ effects on human lymphomas. Treatment with 
the selective ERβ agonist DPN significantly suppressed lymphoma growth in grafting 
experiments using Granta-519 Mantle cell lymphoma (MCL) and Raji Burkitt lymphoma 
(BL) cells in immunocompromised (NOD/SCID gamma) mice in comparison to vehicle 
treated mice. Importantly, activation of ERβ inhibited vascularization. Furthermore, using a 
disseminating Raji BL cell line, we showed that ERβ activation reduced dissemination of 
subcutaneous grafted tumors. We also showed by immunohistochemistry that ERβ is expressed in 
primary MCL tumors. These results suggest that targeting ERβ with agonists may be valuable in 
the treatment of some lymphomas, affecting several aspects of the malignant process including 
proliferation, vascularization and dissemination. 
In Paper III, we showed that when grafting human DLBCL cells to NOD/SCID gamma 
mice, tumor growth was faster in males compared to females. We also demonstrated high 
expression of ERβ1, with small or no ERα expression in DLBCL cells. Furthermore, when 
treating mice grafted with human DLBCL cells with the selective ERβ agonist 
diarylpropionitrile (DPN), lymphoma growth was significantly suppressed. Furthermore, 
ERβ1 expression analysis in primary DLBCL tumors from patients by immunohistochemistry 
revealed nuclear or cytoplasmic expression of ERβ1 in more than 86% of the cases. No 
  
statistical significant correlation of neither nuclear nor cytoplasmic ERβ1 expression to age, 
gender, the International Prognostic Index and DLBCL subtype was observed. Nevertheless, 
high cytoplasmic together with low nuclear expression of ERβ1 was found to be a favorable 
prognostic factor for overall survival (P=0. 03) in DLBCL patients treated with Rituximab 
and CHOP.  
In conclusion, the studies presented in thesis contribute to an explanation of the clinically 
observed lower incidence and better prognosis of lymphomas in women than men. This 
highlights a significant role for estrogens, particularly ERβ signaling, in the pathology of 
NHL. We also suggest that selective ERβ agonists might be a new and useful therapeutic 
approach for treatment of ERβ expressing lymphomas. 
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1 BACKGROUND 
1.1 NUCLEAR RECEPTORS 
Nuclear receptors (NRs) are intracellular receptors out of which almost all are ligand-
controlled transcription factors that play an important role in many physiological functions 
such as metabolism [1], immune response [2], reproduction [3] and development [4]. Apart 
from their functions in normal physiology, NRs have been identified to play an important role 
in many pathological processes, such as cancer, metabolic and inflammatory diseases [5]. In 
humans, 48 NRs have been identified [6] (Table 1), and these receptors now represent one of 
the most important therapeutic drug targets for human diseases, for example diabetes, cancer, 
heart disease, as well as for lifestyle and behavioral conditions [7, 8]. 
NRs can be split into 3 major classes: Class I is known as the steroid receptor family, which 
binds to steroids, for example estrogens. Class II is known as the thyroid /retinoid receptors 
family, which binds to non-steroids e.g thyroid hormones and the third class is termed the 
orphan receptor family which may not have a ligand (defined as true orphan NRs) or where 
the ligand has yet not been identified [9-11]. The steroid hormone receptor family that 
include estrogen (ER), androgen (AR), progesterone (PR), glucocorticoid (GR) and 
mineralocorticoid receptors (MR) generally bind as homodimers to inverted hexamer 
sequences separated by 3 nucleotides present in target genes. NRs are transcription factors 
that share a common overall structure comprising of 3 main domains, namely the N-terminal 
domain (NTD), a central DNA binding domain (DBD) and a C-terminal ligand binding 
domain (LBD). The NTD domain has an active transactivation region that contributes to 
transcription of target genes. The DBD contains two Zn-finger motifs responsible for DNA 
binding specificity and the LBD harbors the ligand binding pocket and has a ligand 
dependent transactivation function [12]. NRs generally have a nuclear localization but are for 
some NRs localized in the cytoplasm before binding its cognate ligands. This is particularly 
the case for GR, AR and MR which are localized in the cytoplasm in the absence of ligand 
but upon ligand binding translocate to the nucleus. In contrast ER and PR are predominantly 
present in the nucleus also in the unliganded state [13]. 
NRs bind specific DNA response elements in regulatory regions of target genes (called 
hormone responsive elements (HREs) and regulate transcription in response to ligand binding 
by recruiting co-regulatory molecules that subsequently modify the chromatin and contact the 
basal transcription machinery [14, 15]. Coregulators, which is the universal term for 
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coactivators and corepressors, are receptor interacting proteins that regulate the 
transcriptional activity of nuclear receptors on target genes or may modify the chromatin 
[16]. NR may also regulate transcription by modifying the activity of other transcriptional 
factors. This leads to either stimulation or repression of transcription. In contrast to other 
transcriptional factors, the activity of most NRs, are regulated by binding to their 
corresponding ligands. These are usually small lipophilic molecules that easily penetrate 
biological membranes. In addition to regulation by ligand, NR activity may be regulated by 
post-translational modification, such as phosphorylation or acetylation [17]. Increasing 
evidence also reveals that NRs may act through non-genomic actions by directly modifying 
signaling mediated by kinases e.g. PKC and MAPK [18]. NR genes are present and expressed 
in some of the simplest animal organisms, but are missing  in fungi, plants and 
choanoflagellates, the closest known relatives of metazoans [19].  
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Table 1 Members of the human nuclear receptor adapted and modified from [6]. 
Name Abbreviation Example of Ligands 
Androgen receptor AR Testosterone, flutamide 
Constitutive androstane receptor CAR Xenobiotics, phenobarbital 
Chicken ovalbumin upstream COUP-TFI, COUP-TFII Orphan 
DSS-AHC critical region on the 
chromosome gene 1 
DAX-1 Orphan 
Estrogen receptor ERα Estradiol-17β, tamoxifen, raloxifene 
 ERβ Estradiol-17β, various synthetic 
compounds 
Estrogen receptor-related 
receptor 
ERR α Orphan 
 ERRβ, ERRγ DES, 4-OH tamoxifen 
ErbA2-related gene-2 EAR2 Orphan 
Farnesoid X receptor FXRα Bile acids, fexaramine 
 FXRβa Lanosterol 
Germ cell nuclear factor GCNF Orphan 
Glucocorticoid  receptor GR Cortisol, dexamethasone, RU486 
Human nuclear factor 4 HNF4α, HNF4γ Orphan 
Liver X receptor LXRα, LXRβ Oxysterols, T091317, GW3965 
Mineralocorticoid  receptor MR Aldosterone, spirolactone 
Neuron-derived orphan receptor 
1 
NOR1 Orphan 
Nerve growth factor-induced 
factor B 
NGFI-B Orphan 
Nur-related factor 1 NURR1 Orphan 
Photoreceptor-specific nuclear 
receptor 
PNR Orphan 
Peroxisome proliferatoractivated 
receptor 
PPARα Fatty acids, leukotriene B4, fibrates 
 PPARβ Fatty acids 
 PPARγ Fatty acids, prostaglandin J2, 
thiazolidinediones 
Pregnane X receptor PXR Xenobiotics, 16α-cyanopregnenolone 
Progesterone  receptor PR Progesterone, medroxyprogesterone 
acetate, RU486 
Retinoid X receptor RXRα, RXRβ, RXRγ Retinoic acid 
Reverse erbA Rev-erbα Orphan 
 Rev-erbβ Orphan 
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Retinoic acid receptor-related 
orphan receptor 
RORα Cholesterol, cholesteryl sulfate 
 RORβ Retinoic acid 
 RORγ Orphan 
Retinoic acid receptor RARα, RARβ, RARγ Retinoic acid 
Steroidogenic factor-1 SF1 Orphan 
Short heterodimeric partner SHP Orphan 
Testis receptor TR2, TR4 Orphan 
Tailless TLL Orphan 
Thyroid hormone receptor TRα, TRβ Thyroid hormones 
Vitamin D receptor VDR Vitamin D 
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1.2 ESTROGENS 
Estrogens are steroid hormones synthesized from cholesterol and are present physiologically 
mainly in the form of 17β-estradiol (E2), estrone (E1), and estriol (E3). Particularly E2 serves 
as the main female sex hormone and acts locally and systemically on target organs and cells. 
However, estrogens are present both in men and women and serve important functions in 
both sexes. In postmenarche to premenopausal women, the ovaries are the main site of 
estrogen synthesis producing the predominant estrogen, E2, while in postmenopausal women 
estrogens derive from androgens by aromatization in peripheral tissues of adrenal-derived 
androgens. In adult males, estrogens are mainly formed from aromatization of gonadal 
produced testosterone. The most potent and dominant estrogen is E2 with weaker activity of 
E1 and E3. Estrogens play a key role in controlling development, sexual behavior and 
reproductive functions, but also have significant roles in the physiology of a wide range of 
other tissues and organs, including the cardiovascular, nervous, the immune systems, as well 
as in bone metabolism [20]. In addition to the effects of estrogens on normal cells and normal 
physiology, estrogens also play an important role in various pathological processes, including 
cancers, particularly breast, ovary, uterus and prostate cancer [21, 22]. 
1.3 ESTROGEN RECEPTORS 
The biological effects of estrogens such as cell growth, reproduction, development and 
differentiation  are mediated by two specific estrogen receptors, α (ERα) and β (ERβ), which 
belong to the steroid receptor family and to which E2 binds with similar affinity [23]. 
Estrogenic effects can also be mediated by a membrane associated-couple protein, the G 
protein estrogen receptor 1 (GPER1) [24]. The classical ERα was first cloned in 1986 [25], 
while the second ER, ERβ, was discovered and cloned in 1996 from rat prostate [26]. ERα 
and ERβ are transcribed from different genes located on separate chromosomes (6 and 14, 
respectively) [27, 28] and display discrete expression patterns as well as partially distinct 
ligand specificities [29]. The three main domains of the NRs as described above can for the 
ERs be sub-divided into six functional structural domains, A-F [30, 31] (Fig. 1). The A/B-
domain contains the activation function 1 (AF-1), which is hormone-independent. The C-
domain holds the DBD, the D-domain or hinge region contains nuclear localization signals 
and interacts with AP-1, and the E/F-domain is the LBD with a ligand-dependent activation 
function, AF-2 [32, 33]. In mammalians, ERα is expressed in reproductive tissues (uterus, 
breast, ovaries, testis), kidney, bone, white adipose tissue and liver, while ERβ has been 
found to be expressed in many tissues, including the central nervous system, the 
cardiovascular system, the immune system, the urogenital tract, the gastrointestinal tract, the 
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kidneys and the lungs [34-36]. However, in many cells/tissues both ERα and ERβ are co-
expressed. e.g breast, ovaries. The generation of three different knockout models, ERα [37], 
ERβ [38] and ERα/ERβ double knockout [39]  have provided vital information about ER 
signaling. For example, it was found that ERα is involved in the development of the uterus, 
mammary gland, bone physiology and male fertility, whereas ERβ is important for neuronal 
development [40]. 
Both ERs function as homodimers but may sometimes heterodimerize and possess a high 
degree homology in the DBD but differs in the N-terminal domain and the LBD [26, 27]. In 
addition to the full length expression of ERα and ERβ, isoforms derived from alternative 
splicing are found both in normal and malignant cells [41]. Splice variants of ERα and ERβ 
have been detected in e.g. normal peripheral leukocytes [42] and many cancers including 
breast [43, 44], endometrial, ovarian and colorectal cancers [45-47]. 
With regard to ERβ, several isoforms (ERβ2 to 5) have been reported. These isoforms are 
generated by alternative splicing in which the terminal exon (exon 8) of the full length wild- 
type ERβ (ER1) has been replaced by unique sequences [48, 49]. The lack of or replacement 
of the last exon (exon 8) has rendered these isoforms unable to bind ligands and unable to 
activate transcription of an estrogen response element (ERE)-driven gene [50]. However, 
they might interfere with ER1 function by acting as dominant negative mutants [51]. For 
example, ERβ2 has been suggested to enhance cell proliferation and invasion [52], and in 
several cancers it was demonstrated that high expression of ERβ2 is associated to poor 
prognosis [53-55]. Like most other members of the NR family, ERs are mainly found in the 
nucleus. However, ERα has also been shown to be present in the cytoplasmic membrane of 
breast cancer cells, where it upon ligand binding can quickly transmit signals affecting cell 
proliferation and survival [56]. Membrane expression of ERβ has also been reported [57]. 
ERβ1 can be found both in the nucleus and cytoplasm of normal and cancerous cells [57, 58]. 
It has been shown that nuclear ERβ1 expression is linked to better overall survival in breast 
cancer, but the function cytoplasmic ERβ has not been adequately explored [59]. 
The classical mode of ER action involves a ligand-induced conformational change in the 
ER that results in ER binding to estrogen response elements (EREs) present in target genes 
and subsequent transcriptional activation [60]. However, by transcription factor cross-talk, 
ligand-activated ERs can also modulate gene expression indirectly through interaction with 
other transcriptional factors (TFs), such as members of the activating protein-1 (AP-1), 
nuclear factor kappa B (NF-B) or specificity protein-1 (Sp1) [41, 61, 62]. In addition, 
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several reports describe an impact of  ER on non- or pregenomic signaling pathways [63-
65]. This involves regulation of various  protein kinase pathways such as PI3K/AKT and 
MAPK signaling [66]. These examples demonstrate that the ERs have the ability to regulate 
cellular responses without binding directly to DNA.  Finally, protein kinase pathways may 
activate ER in a ligand-independent way [67]. 
Figure 1: Schematic representation of the functional domain organization of  
 wild-type  estrogen receptors and their splice variants [68]. 
1.4 ESTROGEN RECEPTOR LIGANDS 
The word “ligand” comes from the Latin word “ligare” which means “to bind. In 
biochemistry and pharmacology, a ligand is defined as an allosteric regulator that is able to 
attach to and shape a biomolecule to serve a biological function, such as a steroid hormone 
which binds to its corresponding NR. There are different classes of ligand, such as high 
affinity agonists that require only low concentrations of ligands to bind with maximal 
occupancy and which elicit a maximal physiological response. Antagonists on the other hand 
are  ligands that bind, but do not provoke a physiological response (e.g., tamoxifen for ER in 
breast tissue) and compete with agonists for binding. Partial agonists or antagonists are 
ligands that do not give rise to a maximal activation or inhibition of a response despite full 
occupancy [69]. 
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E2 is a natural, non/selective ligand for ERα and ERβ and is the most potent natural ER 
ligand, while the two metabolites, estrone (E1) and estriol (E3), are only very weak 
agonists. In addition to the natural ligands, there are several synthetic compounds able to 
function as an agonist or antagonist on the two ERs. For instance, ICI182,780 is considered 
to be a pure antagonist while other ligands are defined as selective estrogen receptor 
modulators (SERM) e.g tamoxin and raloxifene that act as an agonist or an antagonist 
dependent on the tissue [70, 71]. Importantly, the structural differences in the ligand-
binding pockets of ER and ER respectively, have allowed development of subtype 
selective ligands. One of the most widely used ERα selective agonist, propyl pyrazole triol 
(PPT), shows a 410-fold selectivity for ERα versus ERβ [72]. Multiple selective ERβ agonists 
have been synthesized, one of the most well characterized is 2,3-bis (4-hydroxyphenyl)-
propionitrile (DPN) which shows higher relative binding affinity and relative potency for 
ERβ compared to ERα in the range of 70–300-fold [73-75]. To note is that DPN does not 
bind to GPER1 [76]. Another newly developed ER selective agonist is KB9520, which 
shows a 700-fold selectivity for ERβ versus ERα [77] (Fig 2). 
 
Figure 2: Representation of the  structures for some  ER ligands. 
Also, some Phyto-estrogens (plant-derived) compounds have steroid-like structures and 
estrogen-like attributes. Examples of these are genistein, dadzein and glycitein, which are 
the main dietary-derived isoflavones [78]. Many of these compounds show a partial ERβ 
selectivity. For instance, the isoflavone genistein has a 20-fold greater binding affinity for 
ERβ compared to ERα [34, 74, 79].   
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1.5 ESTROGEN RECEPTORS AND CANCERS 
Cancer is an abnormal growth of cells which tend to proliferate in an uncontrolled way and 
often metastasize or disseminate (spread) to other parts of the body via the blood or the 
lymphatic system (Fig 3). Cancer is a major contributing cause of death worldwide. Despite 
advances in the early detection methods and improved therapies, cancer still remains a big 
health challenge. It is a world wide health problem with 12.7 million new cases and 7.6 
million deaths reported for 2008. As the world’s population continues to grow and live 
longer, the incidence of cancer is thought to increase to a sum of 22.2 million cases by the 
year 2030 [80]. 
Hanahan and Weinberg described different features which cancer cells acquire in order to 
sustain their growth and to escape different anti-tumor mechanisms [81]. These features, 
termed “Hallmarks of cancer”, include sustaining of proliferative signaling, evading growth 
suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, 
and activating invasion and metastasis [81]. The primary causes which lead to cancer 
development are environment and lifestyle factors, including smoking, exposure to 
radiation or UV light, high alcohol use, inadequate diet or physical activity, obesity, 
frequent contact with carcinogens (e.g. benzene and asbestos), bacteria or virus infection 
[82-84]. Chronic inflammation is thought to be a major cause of cancer development [85]. 
Genetic factors like mutations in oncogene or tumor repressor genes usually accompany 
cancer development of [86].  
In the cells, the overall effect of E2 is determined by a balance between ERα and ERβ as E2 
binds to both of these receptors with similar affinity. Many tumor cells express ERs and 
several studies have shown that ERs impact on cancer development in several tissue types, 
mainly in endocrine-related reproductive organs [87-90], but also in tissues not generally 
considered to be endocrine-related like lung cancer [91] and colon cancer [92].  
The different expression of the ERs usually account for their effects in cancer tissues. The 
role of ERs in breast cancer pathogenesis are becoming increasingly elucidated by several 
clinical and in vitro studies. Normally both ERs are found in the mammary gland where ERβ 
seems to be predominant in normal breast glands [93]. In breast tissue ERα promotes 
proliferation thereby increasing the risk of tumor development and progression, whereas ERβ 
seems to suppress proliferation and promote differentiation [94, 95]. In early breast cancers, 
the expression of ERα usually increases when going from low to high grade tumors [96], but 
in contrast to ERα, a reduction and loss of ERβ expression was observed when cells 
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transformed from normal tissue to invasive carcinomas [29, 97-99]. Furthermore, It was 
shown that administration of ERβ into T47D breast cancer cells inhibits cancer cell 
proliferation and tumor formation in mouse xenograft models [95, 100]. ER also has 
proapoptotic effects. For example, it has been shown that ERβ induces apoptosis of prostate 
and ovarian cancer cells, while ERα promotes proliferation and survival [94, 101, 102]. ERβ 
has also putative anti-proliferative effects on the ovary and endometrium [103, 104]. It was 
also demonstrated that ovarian cancer shows high expression of ERα when compared to 
normal ovarian tissue, and loss of ERβ correlated with shorter overall survival in ovarian 
cancer [105]. ERβ is also predominantly expressed in the normal colon epithelial cells [106], 
but decreased expression has been observed with the progression of cancer. It has also been 
shown that there is a reduced intestinal tumorigenesis in mice with the spontaneous 
development of intestinal adenomas (ApcMin/+) after treating with diarylpropionitrile 
(DPN), an ERβ specific agonist [107, 108]. An antiproliferative effect of ERβ has also been 
shown in malignant mesothelioma [109, 110]. Similar to e.g. breast and colon, which express 
high nuclear ERβ in normal tissue, but lesser levels after tumor transformation, normal pleura 
expresses high ERβ levels which after tumor progression decrease. It was also indicated that 
ERβ expression was an independent prognostic factor for better survival [109]. ERs have 
been found in lung tissue, however the role of ERα or ERβ in lung cancer is less well-
defined. 
ER is the predominant ER in human peripheral blood leukocytes and spleen [111], and 
therefore generally thought to be the main target receptor for estrogen action in the immune 
system. In line with an antiproliferative effect of ERβ, the absence of ERβ in ERβ knockout 
mice resulted in a myeloproliferative disease resembling human chronic myeloid leukemia 
with lymphoid blast crisis [112]. Monocytes also express mainly ERβ and have been shown 
to be sensitive to estrogen-induced programmed cell death [113]. 
ERβ is also expressed in lymphoid cancer cells and studies have indicated an anti-
proliferative function of ERβ in these cells. In different human lymphoma cell lines including 
both B and T cell lymphomas, ERβ is abundant while ERα is not detectable [77, 111]. It has 
been shown from our lab that ERβ activation in vitro and in vivo leads to the inhibition of 
proliferation and increase of apoptosis in T- lymphoma cells [77]. It has also been reported 
that CLL cells express ER [55]. Furthermore, CLL cells also express the ERβ non-ligand 
binding splice variant ERβ2 [55] and in contrast to the wild-type ER1 it has been reported to 
be a poor prognostic factor for CLL [55], similar to the case for prostate cancer [53]. In 
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prostate cancer cells, it also has been shown to increase proliferation [52]. It has also been  
shown in breast cancer that ERβ2 expression correlated to worse overall survival [59]. 
However, although most studies support antiproliferative and proapoptotic effects of the 
wild-type ERβ1 leading to inhibition of tumor proliferation and survival [95, 114-117], the 
role of ERβ1 in tumor progression is not completely consistent as contradictory results in 
proliferation have been demonstrated. In fact, some studies show a stimulatory effect on 
tumor growth by activation of ER 
Considering that most studies favour anti-proliferative and pro-apoptotic effects of ERβ1 as 
in the case of e.g breast, prostate and colon cancer, and as demonstrated by us for 
lymphomas,  it has been denoted as  a tumor suppressor.  
 
Figure 3: Tumor development stages from normal cells to metastasis. 
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1.6 THE LYMPHATIC SYSTEM 
The human body has two major circulatory systems: the blood and the lymphatic system, 
respectively. The lymphatic system is essentially a drainage system inside the body which 
carries excess fluid and metabolic waste products from interstitial spaces into the blood 
circulatory system. It consists of a network of tissues and organs that include lymphatic 
vessels, lymph and lymph nodes. Except being important for drainage, the lymphatic system 
has an important role in the immune system. Furthermore, many cancer cells use the 
lymphatic system to metastazise/disseminate to other parts of the body [120]. 
The lymph nodes are part of the group of so called secondary lymphoid organs, which except 
the lymph nodes include the spleen, Peyer’s patches, appendix and tonsils. In contrast  to the 
primary lymphoid organs (the thymus and the bone marrow which are responsible for the 
production and maturation of lymphocytes), the secondary lymphoid organs are responsible 
for further maturation of the lymphocytes and initiation of immune responses [121]. Most of 
the lymphomas arise in the lymph nodes, from B (most common), T or Natual killers (NK) 
cells. Figure 4 shows a cartoon of the lymphatic system and lymphoid organs. 
 
Figure 4: The lymphatic system. Reprinted with the permission by the author. Available at: 
https://visualsonline.cancer.gov/details.cfm?imageid=7154 
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The lymphocytes are produced in the bone marrow (B, NK cells) or the thymus (T cells). 
When the lymphocytes are mature, they are released into the blood stream and migrate to the 
secondary lymphoid organs. There are three main types of mature lymphocytes: 
 B lymphocytes, which produce antibodies that attack germs (bacteria, viruses, etc.) 
 T lymphocytes, which have several functions including assisting the B lymphocytes 
to make antibodies and to regulate immune responses. They may also be cytotoxic, 
including killing cancer cells as part of a cancer immunosurveilance system. 
 Natural killer lymphocytes, which are part of the innate immune system and exert a 
cytotoxic effect on viral infected cells and on tumors.  
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1.7 LYMPHOMA 
Lymphoma is a heterogeneous group of malignancies derived from the lymphoid system 
that accounts for roughly 4 % of cancers worldwide [122]. The annual incidence in the 
Western countries is approximately 20 cases per 100,000 persons [123]. According to the 
Swedish Cancer Registry, about 2000 to 2200 new lymphoma cases are diagnosed each year 
in Sweden (http://www.socialstyrelsen.se). In Sweden it is the 8
th
 most common cancer form 
both in men and woman although the number of males are affected slightly more (see 
below). Lymphoma incidence increases with age although it may develop at any age. 
Hodgkin lymphoma (HL) and Burkitt lymphoma (BL) are preferentially seen in young 
adults or children  [124]. Lymphomas derive from lymphocytes. While its primary sites are 
the main or secondary lymphoid organs (lymph nodes most common), it can affect any site 
in the body due to infiltration by malignant lymphocytes.  
The classical division of lymphomas is into Hodgkin (HL) and non-Hodgkin lymphomas 
(NHL). About 90% of the lymphomas are NHL. Today, and especially in the clinic, a 
division based on more clinical lymphoma characteristics is used, classifying lymphomas 
into aggressive or indolent (non-aggressive) types [125]. Most NHL derive from B or T 
cells at various stages of differentiation with 95% of all being of B cell origin [126] and the 
remaining are derived from T cells or NK cells. The most common types of B cell 
lymphomas are diffuse large B cell lymphoma (DLBCL) 30-40%, follicular lymphoma 
(FL) 20%, B-cell chronic lymphocytic leukemia (CLL) 7%, mantle cell lymphoma (MCL) 
5-10%, and Burkitt lymphoma (BL) 2%. The various B lymphomas arise during different 
steps of B lymphocyte differentiation (depicted in Fig. 5). 
 
 
  15 
 
 
Figure 5: B cell development stages and relation to biology of lymphoma. CLL (chronic lymphocytic 
leukemia),  SLL (Small lymphocytic leukemia), GCB-DLBCL (Germinal center B cell like diffuse large B-cell 
lymphoma), FL (Follicular lymphoma), MZL (Marginal zone lymphoma), ABC-DLBCL (Activated B cell like 
diffuse large B-cell lymphoma), MM (Multiple myeloma), BL (Burkit lymphoma) and MCL (Mantle cell 
lymphoma) Adapted and modified  [127]. 
In most cases, the cause of lymphoma is unknown, although several risk factors for B-cell 
lymphomas have been described like age, ethnicity, gender, viruses, bacterial infections, life 
style, impaired immune function, such as immunodeficiency and autoimmune disease. 
Patients who are treated with immunosuppressive drugs following solid organ or 
hematopoietic stem cell transplantation are at substantially increased risk (30–50 times) to 
develop NHL [128, 129], especially during the first year after transplantation [130]. Systemic 
lupus erythematosus and rheumatoid arthritis has also been associated with B cell lymphoma 
[131]. Certain lymphomas are related to viral infections, such as Epstein-Barr virus 
(particularly BL) and hepatitis C virus [132]. Infection with EBV is highly prevalent in the 
adult population with approximately 90% of individuals in developed countries having 
evidence of a previous EBV infection by age of 40. Patients infected with HIV show a 
significantly increased risk of B cell lymphomas [133]. Bacterial infections by e.g. 
Helicobacter pylori has also been associated to NHL [134]. Interestingly, the incidence of 
NHL increased for two decades by 3-4% yearly until the mid 90-ties after which the increase 
has leveled off [135]. The reason for this is unknown. 
Several classifications have been described for NHL according to their histologic 
characteristics, but the most recent system is the fourth edition of the WHO classification of 
tumors of haemopoietic and lymphoid tissues, published in 2008 (Table 2) [136] 
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Table 2. 
Subtypes of non-Hodgkin lymphoma, according to the 2008 WHO classification 
Name Diseases 
B-cell lymphomas 
Precursor B cell Precursor B-cell lymphoblastic leukemia or lymphoma 
Mature B cell 
Chronic lymphocytic leukemia/small lymphocytic lymphoma; lymphoplasmacytic 
lymphoma; splenic marginal-zone lymphoma; extranodal marginal-zone B-cell 
lymphoma of mucosa-associated lymphoid tissue; nodal marginal-zone B-cell 
lymphoma; follicular lymphoma; mantle-cell lymphoma; diffuse large B-cell 
lymphoma; Burkitt's lymphoma 
B-cell proliferations 
of uncertain 
malignant potential 
Lymphomatoid granulomatosis; post-transplantation lymphoproliferative disorders 
(polymorphic) 
T-cell and NK-cell lymphomas 
Precursor T cell Precursor T-cell lymphoblastic leukemia or lymphoma 
Extranodal mature T 
cell and NK cell 
Mycosis fungoides; cutaneous anaplastic large-cell lymphoma; extranodal NK-cell 
or T-cell lymphoma; enteropathy-type lymphoma; hepatosplenic lymphoma; 
subcutaneous panniculitis-like lymphoma; primary cutaneous CD8-positive 
lymphoma; primary cutaneous γ/δ T-cell lymphoma; primary cutaneous CD4-
positive lymphoma 
Nodal mature T cell 
and NK cell 
Peripheral T-cell lymphoma, not otherwise specified; angioimmunoblastic 
lymphoma; anaplastic large-cell ALK-positive lymphoma; anaplastic large-cell 
ALK-negative lymphoma; adult T-cell leukemia/lymphoma 
 
Chemotherapy with mustine for NHL malignancy was first used in 1940’s and resulted in a 
dramatic but transient reduction in tumor mass [137]. Since then a number of advances in 
lymphoma treatment have contributed to improved outcomes for people affected by NHL 
and HL with decreasing mortality rates observed mainly during the last 5-10 years or so. A 
significant improvement during the last decade was made possible with the introduction of 
an anti-CD20 monoclonal antibody, rituximab, which has been utilized widely in the 
treatment of B cell lymphomas leading to significantly better outcomes, which in part have 
contributed to the reduced mortality rates. Today overall five-year survival rate in Sweden 
for all HL subtypes is around 90%, while that for NHL it is around 72% and it has increased 
during the last 15 years (1996-2011) with about 15% (Stockholm Gotland Cancer region 
report 2013, www.cancercentrum.se). However and notably, still about one third of patients 
with NHL don’t respond or become therapy resistant [138]. Furthermore, the overall 
survival rate is very much dependent on lymphoma subtype, age and grading with e.g. MCL 
and T cell lymphomas having a poor outcome [139]. The need for new therapies utilizing 
new drug targets, particularly for NHL’s with poor prognosis or which become resistant to 
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present therapies, is therefore still high. In line with this several new drugs targeting 
especially intracellular signaling pathways important for lymphoma proliferation and survival 
are under development (together with immunotherapies) or have recently been introduced 
(still not used as first line therapies). One example of a recently developed drug affecting an 
intracellular signaling pathway is Ibrutinib, which is a Bruton tyrosine kinase inhibitor 
preventing B-cell receptor signaling thereby inhibiting B-cell proliferation and survival [140]. 
However, in a recent study, still 32% of first-line treatment resistant MCL did not respond to 
the BCR signaling inhibitor Ibrutinib [141], suggesting that a subpopulation of MCL is 
resistant even to one the most newly developed drugs. Therefore, the need for additional 
improved therapies, preferentially utilizing new concepts, is still there. 
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1.8 LYMPHOMA INCIDENCE IN RELATION TO GENDER AND 
ESTROGENS 
Several epidemiological studies demonstrate a gender differences with respect to both the 
incidence and prognosis of NHL [142-145]. The overall incidence of NHL is 30% lower in 
women compared to men although the ratio between males and females differ for the 
different lymphoma subtypes or even with age [146]. NHL with the highest male to female 
incidence ratio is seen among e.g. MCL and BL with ratios of 3-6:1. In contrast, FL shows no 
difference in incidence between genders. The most common lymphoma type, DLBCL, show 
a male to female incidence ratio of 1.2:1 to 1.6:1 [147, 148]. A relative high male to female 
ratio is also seen among T cell lymphomas where a male/female incidence rate ratio of 1.8 for 
T-cell peripheral lymphomas was reported [149]. The incidence of CLL in adult males is 
nearly two times higher than that in women. Interestingly, it has also been reported, and 
similar to humans, that canine lymphoma is significantly more common in male dogs 
compared to female dogs [150]. 
Various additional population based studies have shown that that reproductive factors, 
particularly estrogens, may explain the gender difference in NHL incidence [151, 152]. 
Although not fully consistent, epidemiological data from several studies in females show an 
association between reproductive hormonal factors and oral contraceptives with a reduced 
risk for NHL with up to 50% [146, 153, 154]. Furthermore, pregnancy has also been 
reported to reduce the incidence of NHL, supporting an involvement of female sex 
hormones in NHL development [146, 155]. It has also been proposed that hormone 
replacement therapy may be associated with a reduced risk of NHL in postmenopausal 
women [156-158]. Recently in a Swedish population-based study, it was demonstrated that 
females younger than 52 years of age (average age for menopause) have a better overall 
survival of the NHL subtype DLBCL compared to men at the same age. However, the 
gender difference disappeared after menopause [159]. Furthermore, gender also seems to 
influence response to standard treatment, as some studies suggest that the male gender is 
associated with a poorer treatment outcome in patients with NHL [160-162]. It line with 
this it was demonstrated that women show a better response to R-CHOP therapy compared 
to men [163]. This gender-associated response to therapy is not limited to one single 
therapy but seen for several drugs [164]. However, some of the gender difference in therapy 
response may relate to  gender specific metabolism of the drugs used [165].  
  19 
 
Although there is strong evidence from epidemiological data that reproductive factors and 
particularly estrogens have a protective effect on lymphoma development as described above, 
lymphomas are not generally considered as hormone-related cancers. This despite that 
several lymphoma subtypes have been shown to express ERs [77, 112]. In addition, it has 
been shown that normal lymphocytes that express ERs were regulated by estrogen [166]. 
Subsequently, very little is known about the molecular mechanism of sex hormone action on 
lymphomas and the idea of exploring hormone therapies in lymphoma treatment has not 
really been recognized. 
Malignant lymphoma (excl. Hodgkin's lymphoma) 
Number of cases per 100 000 in Sweden 
 
Figure 6. The incidence of malignant lymphoma per year in Sweden defined by age. 
Source: Socialstyrelsens statistikdatabas; Cancer i siffror, 2013 
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2 AIM OF THE STUDY 
The overall aim of my research project was to investigate the effects of estrogens, particularly 
selective ERβ agonists, on tumors of lymphoid origin and to study the mechanisms of action 
of ER selective agonists and their usefulness for inhibiting growth of murine and human 
lymphoma. More specifically the following aspects were studied. 
The specific aims were: 
 To look into the impact of gender in an experimental lymphoma animal model in 
vivo. To determine ER expression and to investigate the effects of selective ER 
agonists on murine lymphoma tumor proliferation in vitro and in vivo. 
 Establish in vivo models in mice to test ERβ agonists effects on human non-Hodgkin 
lymphoma (NHL) and their mechanisms. 
 To analyze the impact of gender, ERβ1 expression  and its correlation to clinical 
parameters of DLBCL 
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3 MATERIAL AND METHOD 
3.1 CELL LINES AND PATIENTS 
In this thesis six different types of lymphoma cell lines were used representing four types of 
NHL. A murine T lymphoma cell line termed EG7 [167], a Mantle cell lymphoma (MCL) 
cell line (Granta 519) [168], two Burkitt lymphoma cell lines (Raji and Ramos) [169] and two 
Diffuse Large B cell lymphoma (DLBCL) cell lines (SU.DHL4 and  U2932) [170, 171]. 
SU.DHL4 is considered to be a germinal center B cell like (GCB) DLBCL while U2932 is an 
activated B cell type (ABC) DLBCL. All these cell lines were shown by qPCR and/or 
immunostaining to express relative high amounts of ER mRNA and protein, but low or no 
ER. Primary MCL material was from Karolinska University Hospital and tissue micro-
arrays of primary DLBCL’s were from two separate cohorts (Uppsala Akademiska Hospital 
and Skåne University Hospital, respectively). 
3.2 LABORATORY ANIMALS AND TUMOR GRAFTING 
It was in mid-1960s when the first in vivo models for tumors were developed that were mouse 
leukemia models [172]. Many inbred, outbred and transgenic strains are used now a days in 
the labs. Among all animal models, Mus musculus is the most extensively used species for 
transplantation of both mouse and human tumors. These are mammals, small in size and easy 
to handle. They multiply rapidly and one of the most significant advantages is that the whole 
genome is sequenced and resembles the human genome to a big extent.  
C57Bl/6J mice (8-10 weeks of age) were bought from Charles River (Lille Skensved, 
Denmark). NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ commonly known as NOD scid gamma 
(NSG) mice [173] and ERβ−/− knockout (BERKO) [38] mice were bred at the Department of 
Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden. NSG mice lack B and 
T cells as well as NK cells. Macrophages number is reduced in NSG mice and they are also 
deficient in cytokine signalling. They are very reciprocal for tumor cell grafting. 
For tumor grafting, 0.5 to 15 x 10
6
 lymphoma cells of different lymphoma types were 
inoculated subcutaneously once daily into the right flank of the mice. Hormone treatment 
started from the day after injection of lymphoma cells (Paper I) or when lymphomas were 
first palpaple (Paper II and Paper III). Mice were injected subcutaneously in the left flank 
with selective agonists of ERs (PPT, DPN, KB9520), non-selective E2 or antagonist 
(ICI182,780). (See individual paper for details). Tumor growth was assessed daily and tumor 
volume (TV) was calculated as TV (mm
3
) = 0.5 x length (mm) x width
2
 (mm
2
) using a 
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caliper. Experimental manipulations of the mice were, according to the ethical approval and 
local Karolinska Institutet regulations. No signals of pain or physical discomfort among the 
mice were noted. Figure 7 shows a flow chart for animal experiments. 
 
 
Figure 7: Flowchart for experiments 
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3.3 IMMUNOHISTOCHEMISTRY  
 
IHC is the most commonly applied immunostaining technique. It is widely used in the basic 
and clinical research to identify presence and localization of biomarkers and differentially 
expressed proteins in the different tissues. From animal experiments, tissue samples were 
fixed in 4% paraformaldehyde overnight, rinsed in 50% ethanol and embedded in paraffin for 
sectioning. Primary lymphoma specimens were taken at diagnosis for diagnostic purposes, 
formalin fixed and embedded in paraffin. See individual papers for details regarding 
conditions used (Paper I-III). In Paper III, normal liver, which lacks ERβ expression as well 
as omission of the primary antibody served as negative controls for ERβ1 staining. Human 
tonsils (positively stained germinal centers) were used as positive control. To confirm the 
ERβ specificity of the 503 antibody and the PPG5/10 antibody used for 
immunofluorescence/immunohistohemistry, murine hepatoma cells Hepa1c1c7 or human 
Breast cancer cells MDAM231 were stained for ERβ and showed to be negative, unless the 
cells were transfected with ERβ-expressing vector, confirming the ERβ specificity of the 503 
antibody  and the mouse monoclonal anti- human ERβ (PPG5/10) antibody used. To note is 
that both anti-bodies used to only recognize ERβ1 and not the splice variants. The tissue 
microarray (TMA) and control slides were evaluated independently by two investigators, out 
of which one is an experienced hematopathologist. 
3.4 QUANTITATIVE POLYMERASE CHAIN  REACTION 
SYBR Green based quantitative polymerase chain reaction (qPCR) was used to measure gene 
expression in real time. It is based on detection by the fluorochrome SYBR Green which 
binds non-specifically to produced PCR products. The SYBR Green based qPCR assay is a 
sensitive and reliable method to determine the relative level of specific RNA between two 
samples. To quantify the PCR product, we used the standard 2-ΔΔCt method [174]. The 
specificity of PCR product was examined by dissociation curves and results were calculated by 
the 2−ΔΔCt method. The final exponential value 2-ΔΔCt represents the relative fold change 
between two samples normalized to the Ct values from a housekeeping gene. Three of the 
most commonly used housekeeping genes GAPDH, 36B4 and 18S, were used in our studies, 
due to high and stable expression levels in the used cell lines and tumor materials. We 
obtained  the same results with all used housekeeping genes.  
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4 RESULTS AND DISCUSSION 
4.1 PAPER I: 
Effect of ligand-activated estrogen receptor β on lymphoma growth in vitro and in vivo 
As mentioned above, several epidemiological studies have shown a gender difference in NHL 
incidence as well as suggested a protective role for estrogens in NHL development. However, 
almost no experimental studies, particularly not in vivo, have been performed to establish an 
experimental animal model that resembles this gender difference and to evaluate the 
mechanism of action of estrogens and involvement of ERs in this response. This is  despite 
that ERβ is expressed in immune cells and numerous studies have identified an anti-
proliferative effect of ERβ [36, 110, 175]. In our first experiments, we observed that a murine 
T cell lymphoma (EG7) grew faster in male mice as compared to female mice, a difference 
that was abolished following ovarioectomy. This suggested that estrogens may exert an anti-
proliferative effect on EG7 lymphoma growth. When analyzing ER expression in the murine 
T- and in several human B-cell lymphoma cell lines, we detected relatively high ERβ 
expression with minor or no ER expression. This is in line with previous studies that 
showed that normal lymphoid cells, mainly express ERβ [111]. Furthermore and notably, 
this in contrast to many other cells, e.g. breast, prostate and colon, which seem to 
drastically down-regulate or loose ER expression when transformed into cancer cells 
[176]. This has been claimed to be due to ERβ promoter methylation occurring during the 
malignant transformation [177]. In addition, we examined the effects of E2 and selective ERα 
and ERβ agonists on lymphoma growth in culture and in vivo. In culture, selective ERβ 
agonists exerted a  anti-proliferative effects while E2 only showed a weak anti-proliferative 
effect. A selective ERα agonist, propylpyrazole trisphenol (PPT), did not influence the 
proliferation of the EG7 T-lymphoma cells. We also investigated whether lymphoma growth 
may be suppressed in vivo by selective ERβ agonist treatment. Mice grafted with the murine 
lymphoma cells were treated with the selective ERβ agonists DPN or KB9520. Both ERβ 
selective agonists strongly inhibited lymphoma growth in vivo while the ER selective 
agonist PPT had no effect and E2 only had a minor effect. Further analysis showed that the 
reduced tumor size of EG7 lymphoma seen following either DPN or KB9520 treatment was 
due to reduced proliferation and increased apoptosis. The antiproliferative effect of ER 
activation is in line with previous studies demonstrating that administration of ERβ into 
breast cancer or colon cancer cells inhibits cancer cell proliferation and tumor formation in 
mouse xenograft models [95, 178]. Furthermore, it has been shown that ERβ agonist also 
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induces apoptosis in prostatic epithelial cells of estrogen-deficient aromatase knockout 
mice [179]. That lymphoma cells seem to maintain high ERβ expression is a positive 
feature as targeting ER may be a successful approach in the development of a new 
lymphoma therapy. 
In summary, to our knowledge this is the first demonstration in an experimental in vivo model 
of the gender difference in lymphoma development and the influence of estrogens on 
lymphoma growth. We have shown  that ligand-activated ERβ by  the selective ERβ agonists 
can suppress tumor growth and induces apoptosis. Furthermore, it gives a possible 
explanation to the clinically observed lower incidence and better prognosis of lymphomas in 
women than men. Finally, the results suggest that ERβ agonists may be useful in the 
treatment of lymphomas, especially considering that lymphoma cells seems to maintain ER 
expression.  
4.2 PAPER II: 
Inhibition of lymphoma vascularization and dissemination by estrogen receptor β 
agonists 
In the second paper, we extended our studies to see if the anti-proliferative effect following 
ER activation in vivo seen on a murine T cell lymphoma (paper I) also is valid for human B 
cell lymphomas. For this purpose, we studied two lymphomas, Mantle cell lymphoma (MCL) 
which is one of the NHL types with the poorest prognosis [139], and Burkitt lymphoma (BL). 
Both MCL and BL are two of the lymphoma subtypes that show the high male to female 
incidence ratio [143]. NOD/SCID gamma (NSG) mice were  grafted with human MCL cells 
(Granta-519) or Raji BL cells and were treated with the ERβ agonist DPN.  ERβ agonist 
treatment inhibited tumor growth of both the MCL and BL. In a way to investigate the 
mechanism by which the ER agonist inhibited lymphoma growth, we studied genes in 
Granta-519 MCL whose expression was regulated following selective ERβ agonist (DPN) 
treatment and previously have been demonstrated to be important for B cell proliferation and 
survival, namely BAFF and GRB7 [180, 181]. Both these genes were significantly down-
regulated following ER agonist treatment in vivo. Furthermore, as tumor stimulated 
vascularization plays an vital role in tumor progression and metastasis [182-184], including 
for the development and progression of hematologic malignancies [185], we examined if this 
process was affected by the treatment with the selective ERβ agonists. We demonstrated that 
ERβ agonist treatment reduced vascularization, both with regard to lymphangiogenesis and 
angiogenesis as determined by reduced expression of markers for these processes. The 
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reduced vascularization could be explained by a reduced expression of VEGF-C, previously 
known to be involved in the process of tumor vascularization [186]. Tumor angio- and 
lymphangiogenesis is a key process enhancing tumor cell dissemination [187]. We also could 
show by using a disseminating Raji BL cell line [188] that ERβ agonist treatment reduced 
dissemination in vivo. 
Growth of cancers in vivo require contact between tumor cells and the cells of the tumor 
microenvironement, such as immune, endothelial and stromal cells, which provide multiple 
regulatory signals to cancer cells [189]. Although previous studies have shown expression of 
ERβ in immune and endothelial cells [36, 190], the effect of ERβ in the cells of the 
microenviroment on lymphoma growth was not clear. We by using mice deficient  in ERβ 
(BERKO mice) [38] could show that ERβ agonist effects on the tumor microenvironment did 
not influence the tumor response as lymphomas grafted to wild-type and BERKO mice 
responded equally well to ERβ agonist treatment. Finally we demonstrated nuclear expression 
of ERβ protein in biopsy sections from MCL patients. 
Despite a significant progress in MCL research, the understanding of MCL pathogenesis is 
not complete, and considering the poor prognosis, new therapeutic approaches are required 
[191]. In summary, our results suggest that selective ERβ agonist treatment inhibits 
lymphoma growth, angiogenesis, lymphangiogenesis and dissemination and may therefore be 
useful in the treatment of at least a selected number of lymphomas, including MCL and BL. 
4.3 PAPER III 
 Estrogen receptor β1  in diffuse large B-cell lymphoma growth and as a prognostic 
marker 
In our third paper, we focused our studies on Diffuse Large B Cell Lymphoma (DLBCL). 
DLBCL is the most common form of NHL and usually presents as an aggressive form. 
DLBCL also shows a higher incidence and poorer prognosis in males vs. females [147, 148]. 
Despite improved treatment strategies of DLBCL, around 1/3 of the patients do not respond 
or become resistant to standard therapy [138], which highlights a need for alternative 
therapies. In various studies, the male sex has been associated to a negative impact on overall 
survival and tumor progression in DLBCL when treated with current therapy [161, 162]. 
Furthermore, in several studies it was found that age is a negative prognostic factor for 
overall survival [192, 193], and in a more selected material it was shown that the effect of age 
was a negative prognostic factor for men at all ages but only for women 60 years or older 
(Berglund, unpublished data). 
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DLBCL consists of two main subtypes, namely activated B cell like (ABC)- and germinal 
center B cell like (GCB)-DLBCL, where the former one is characterized by high NF-ҝB 
expression [194] and the latter one for low NF-ҝB expression. NF-B signaling has been 
shown to be important for proliferation and survival and the ABC-DLBCL usually presents 
as a more aggressive form with poorer prognosis [194, 195]. In this paper, we show that 
when grafting the ABC-DLBCL cells (U2932) to male and female mice, U2932 DLBCL 
tumors grew faster in the males, possibly relating to the gender difference seen in the clinical 
situation for DLBCL incidence and prognosis. Treating tumors derived from the ABC-
DLBCL U2932 cells or the GCB-DLBCL SU.DHL4 with the ER selective agonist DPN 
resulted in both cases in inhibition of tumor growth. Notably, this was despite the major 
difference in NF-B signaling between the DLBCL subtypes, demonstrating that ER 
agonists are effective in reducing tumor growth independent of the level of NF-B activity. 
Considering that ERβ has characteristics of a tumor repressor, we investigated ERβ1 
expression by immunohistochemistry in clinical DLBCL samples and correlated nuclear and 
cytoplasmic ERβ1 expression to clinical data and overall survival. 130 primary DLBCL cases 
were analyzed. Importantly, very few (14%) of the DLBCLs do not express nuclear or 
cytoplasmic ERβ1, indicating that most DLBCLs may be responsive to endocrine therapy by 
ERβ agonists. It is also interesting that most of the DLBCL retain ER1 expression as it has 
previously been suggested that ER expression is commonly lost upon malignant 
transformation, possibly due to promoter methylation of the ERpromoter [177, 196]. 
However, no statistical significant correlation of neither nuclear nor cytoplasmic ERβ1 
expression to age, gender, International Prognostic Index (IPI) or  DLBCL subtype was 
observed. Nevertheless, there was a tendency that extra-nodal tumor sites express less nuclear 
ERβ1 compared to nodal sites. Larger cohorts are most likely necessary to fully establish 
whether a correlation exists or is lacking between ERβ1 expression and one or several of the 
clinical parameters. In our IHC studies of primary DLBCL, we observed a variation of ER1 
distribution between nuclear and cytoplasmic localization. The relative role for nuclear vs. 
cytoplasmic ER1 for responsiveness is still unclear. However, we found that DLBCL’s with 
low nuclear and high cytoplasmic ER1 expression correlated to a significant better overall 
survival as compared to DLBCL’s that had high nuclear and low cytoplasmic ER1 
expression (P=0. 03). Considering ER to be primarily a nuclear receptor acting (mainly) 
through genomic mechanisms, these results are surprising. However, ER1 expression is not 
uncommonly found in the cytoplasm in other cancers [197]. 
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5 CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES 
Estrogens have important physiological functions in numerous  tissues of the body, but are 
also involved in the pathogenesis of many diseases. Estrogen effects are mediated by two 
well know receptors called ER and ER, respectively. It has been shown in several  studies 
that the two ERs influence cancers like prostate, breast and colon but in opposite direction. 
While signaling via ERα has pro-proliferative properties in cancers, ERβ has anti- 
proliferative and pro-apoptotic effects. The purpose of this thesis was to increase our 
understanding of estrogen effects, the role of the two ER’s  in lymphomas and to identify 
molecular mechanisms and prognostic factors related to ER signaling and expression. 
Furthermore, this may give an explanation for the gender difference in incidence seen for 
most lymphomas.  Finally, we wanted to explore the possibility of using ER agonists as a 
new treatment option in lymphomas. 
To our knowledge, this is the first  thorough study where the impact of  estrogens, the role of 
ER and ER, respectively, and their mechanisms of action have been studied more in depth 
in experimental lymphoma models, particularly in vivo. Based on our findings from both in 
vivo and in vitro experimental studies, and ERthe expression analysis in clinical lymphoma 
material , it was concluded that 
 Both murine T cell lymphoma and human B-cell lymphoma express ERβ. 
 Treatment of T cell lymphoma cells (EG7) in culture with ERβ  selective agonists 
inhibited cell proliferation. 
 Grafted murine lymphoma  (EG7) and human lymphoma (DLBCL) tumor growth is 
estrogen dependent and grew slower in female vs. male mice, a difference that was 
abolished following ovarioectomy. 
 Treatment of mice carrying allografted murine lymphoma (EG7) or xenografted 
human lymphoma (BL, DLBCL and MCL) by selective ERβ  agonists suppressed 
tumor growth, due to decreased proliferation and increased apoptosis. Treatment 
with a selective ERα agonist PPT had no effect on lymphoma growth. Selective 
ERβ  agonist treatment also decreased tumor vascularization (blood and lymphatic 
vessels) and reduced dissemination. 
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 Primary lymphoma material (MCL and DLBCL) express ERβ1 protein, which 
suggests that selective ERβ  agonists may be useful in the treatment of ERβ 
expressing lymphomas. 
 Analysis of ER expression in lymphoma (DLBCL) may be valuable as a 
prognostic factor for overall survival. 
Based on the results we suggest that selective ERβ agonists will be very useful for therapy 
of ERβ-expressing lymphomas and may be utilized alone or in combination with currently 
existing therapies, particularly for lymphomas resistant to present drugs. Furthermore, the 
use of highly selective ER agonists will avoid side effects normally associated with the 
use of un-selective estrogens. The use of selective ER agonists in clinical trials for other 
disease indications has shown that they are safe. The identification of ER expression in 
primary lymphoma biopsies derived from patients and important target genes regulated by 
ER agonists will also provide a tool to predict ER agonist sensitivity, thereby identifying 
patients which will benefit from ER agonist treatment, thus contributing to personalized 
treatment. However, additional studies are required to fully dissect the molecular 
mechanisms by which ERβ affects lymphoma growth, particularly signaling pathways and 
additional target genes involved. This involves e.g. the effect of ERβ signalling on 
dissemination as well as ERβ-mediated regulation of miRNA as dysregulated miRNA 
expression is frequently occurring in lymphomas [198]. To keep in mind is that most likely 
there is no general mechanism by which estrogens via ERβ operate in the different NHL’s. 
Furthermore, as we see weaker responses in vitro compared to in vivo after ERβ agonist 
administration, further studies on the impact of tumor microenviroment on ERβ agonist 
responses are worth to explore. 
In addition, other cohorts of clinical lymphoma material will have to be studied to further 
evaluate nuclear and cytoplasmic ERβ expression and its correlation to clinical parameters, 
especially considering the unexpected results showing a correlation between high 
cytoplasmic and low nuclear ERβ1 expression in R-CHOP treated DLBCL to good 
prognosis. The ERβ expression in lymphoma material can also be correlated to the expression 
of additional markers previously shown to be valuable tools for lymphoma characterization 
and prognosis. Finally, the role of ERβ splice variants in the process of lymphoma growth 
and prognosis should not be forgotten.  
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